Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 10/20 | 0.71 |
| ▸ | HTR3A | P46098 | 3/20 | 0.71 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.71 |
| ▸ | HTR3B | O95264 | 2/20 | 0.71 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.71 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7293857 | 1.00 | CHRNA7 (0.71) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7290441 | 1.00 | CHRNA7 (0.71) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL7288130 | 0.99 | CHRNA7 (0.70) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL10342498 | 0.99 | CHRNA7 (0.70) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL9183102 | 0.99 | CHRNA7 (0.70) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6682650 | 0.94 | CHRNA7 (0.62) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Cadaverine Tartrate SCHEMBL9480676 | 0.93 | CHRNA7 (0.62) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Cadaverine Tartrate SCHEMBL9480682 | 0.93 | CHRNA7 (0.62) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7287511 | 0.93 | CHRNA7 (0.62) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL4198789 | 0.87 | CHRNA7 (0.64) | CHRNA7HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021127642-A1 | SELECTIVE VALORIZATION OF BIOMASS SUGARS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-06-24 | — | — | WO | claimed |
| US-11618763-B2 | Selective valorization of biomass sugars | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-04-04 | — | — | US | disclosed |
| US-20210188890-A1 | SELECTIVE VALORIZATION OF BIOMASS SUGARS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-06-24 | — | — | US | disclosed |
| WO-2021127642-A1 | SELECTIVE VALORIZATION OF BIOMASS SUGARS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-0546181-B1 | INDOLE DERIVATIVES AND THEIR USE AS SEROTONIN ANTAGONISTS | NIPPON SHINYAKU CO LTD (JP) | 1995-08-02 | — | — | EP | disclosed |
| US-5342845-A | Useful as a gastrointestinal motor activity regulator, antimigraine, antipsychotic or antianxiety drug | NIPPON SHINYAKU COMPANY LIMITED (JP) | 1994-08-30 | — | — | US | disclosed |
| US-5237066-A | Reacting quinuclidone with (R)-alpha-methylbenzylamine; reduction with alkali metal borohydride; hydrogenolysis in acid | DELANDE S.A. (FR) | 1993-08-17 | — | — | US | disclosed |
| EP-0546181-A1 | INDOLE DERIVATIVES AND THEIR USE AS SEROTONIN ANTAGONISTS | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1993-06-16 | — | — | EP | disclosed |
| US-5206246-A | Anxiolytic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0353372-B1 | Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1993-02-03 | — | — | EP | disclosed |
| US-5025022-A | Method of treating or preventing schizophrenia and/or psychosis using S-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | A.H. ROBINS COMPANY, INCORPORATED A VA CORPORATION | 1991-06-18 | — | — | US | disclosed |
| US-5017580-A | Memory enhancing-R-N-(1-azabicyclo[2.2.2.]oct-3-yl)benzamides and thiobenzamides | A.H. ROBINS COMPANY, INCORPORATED A VA CORPORATION | 1991-05-21 | — | — | US | disclosed |
| EP-0353372-A1 | Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1990-02-07 | — | — | EP | disclosed |
| EP-0353371-A1 | Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1990-02-07 | — | — | EP | disclosed |
| EP-0311724-A1 | Anxiolytic-R-N-(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1989-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618763-B2 | Selective valorization of biomass sugars | GALE, FBP1, GNE | CHRNA7 3850/4885HTR3A 4081/4885HTR3E 4467/4885 |
| US-20210188890-A1 | SELECTIVE VALORIZATION OF BIOMASS SUGARS | GALE, FBP1, GNE | CHRNA7 3850/4885HTR3A 4081/4885HTR3E 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.